| Pharmaceutical Information |
| Drug Name |
Cidofovir dihydrate |
| Drug ID |
BADD_D00464 |
| Description |
Cidofovir is an injectable antiviral medication employed in the treatment of cytomegalovirus (CMV) retinitis in patients diagnosed with AIDS. It suppresses CMV replication through selective inhibition of viral DNA synthesis.[FDA label] It was manufactured by _Gilead_ and initially approved by the FDA in 1996, but has since been discontinued.[L6223] |
| Indications and Usage |
For the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS) |
| Marketing Status |
approved |
| ATC Code |
J05AB12 |
| DrugBank ID |
DB00369
|
| KEGG ID |
D00273
|
| MeSH ID |
D000077404
|
| PubChem ID |
60933
|
| TTD Drug ID |
D04AAW
|
| NDC Product Code |
14593-840; 71052-483; 73309-228; 82891-006; 82772-002; 23155-216; 73377-064 |
| UNII |
JIL713Q00N
|
| Synonyms |
Cidofovir | HPMPC | GS 504 | GS-504 | GS504 | Cidofovir, Sodium Salt | Cidofovir Sodium | Cidofovir, (R)-isomer | Cidofovir Anhydrous | 1-(3-Hydroxy-2-phosphonylmethoxypropyl)cytosine | 1-((3-Hydroxy-2-phosphonylmethoxy)propyl)cytosine | Vistide | Cidofovir, (+-)-isomer |
|
| Chemical Information |
| Molecular Formula |
C8H18N3O8P |
| CAS Registry Number |
149394-66-1 |
| SMILES |
C1=CN(C(=O)N=C1N)CC(CO)OCP(=O)(O)O.O.O |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
